PropertyValue
?:abstract
  • During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs We review evidence of the ten most recent reports on remdesivir We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention during the COVID-19 pandemic
is ?:annotates of
?:creator
?:journal
  • New_Microbes_and_New_Infections
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Critical reappraisal of remdesivir investigational trials in COVID-19
?:type
?:who_covidence_id
  • #872397
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/w8zmrnkg>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/w8zmrnkg>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all